Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Melanoma/Skin Cancer
•
Medical Oncology
When, if ever, would you consider using encorafenib/binimetinib or vemurafenib/cobimetinib instead of dabrafenib/trametinib for adjuvant treatment of BRAF mutated melanoma?
Related Questions
How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?
What immunotherapy backbone do you utilize for patients with resectable Stage III melanoma when you offer neoadjuvant therapy?
How do you approach patients with advanced resectable basal cell carcinoma for possible use of hedgehog inhibitors?
How do you approach an elderly patient (~80 years) with stage IIC melanoma post resection with oligometastatic brain lesion post intracranial resection which developed 2 years after treatment?
How would you approach a 2 cm malignant primary cutaneous adnexal adenocarcinoma of the axilla s/p resection with positive margin who is unable to undergo additional surgery?
How do you approach patients with metastatic uveal melanoma not a candidate for tebentafusp-tebn?
How do you approach patients with stage III melanoma for adjuvant treatment?
How do you approach patients with malignant melanoma who are disease free on immunotherapy for over 3 years?
How do you approach a patient with recurrent chest wall BRAF(+) mutated melanoma who developed multiple metastatic axillary nodes while on immunotherapy, now post axillary dissection for adjuvant radiation?
How do you approach melanoma patients with a positive sentinel node with extra-nodal extension for definitive surgical management?